ProActa Raises $1.1M
ProActa, which is developing an anti-cancer drug transplanted from New Zealand, has raised $1.1 million in debt and securities, according to a recent regulatory filing. The biotech, which has raised at least $43 million in venture funding since 2004, announced earlier this month that it was starting a second mid-stage clinical trial of a drug for Acute Myeloid Leukemia. ProActa’s investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital of New Zealand, GBS Venture Partners of Australia, Genentech, No. 8 Ventures of New Zealand, and Roche.